Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Omeros Finalizes with FDA Clinical Plan for OMS721 Approval in IgA Nephropathy

americanpharmaceuticalreviewJanuary 21, 2019

Tag: Omeros , OMS721 , IgA nephropathy , monoclonal antibody

PharmaSources Customer Service